NeoGenomics Q2 Revenues up 18 Percent as Firm Beats Analyst Estimates
The firm said that both its test volume and average revenue per test were up year over year, with 295,116 tests performed during the quarter.
Source: genomeweb.com
📰 Moldx Program News
Moldx Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Moldx Program. Real-time updates on events, politics, business and more.
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
25.07.2023 - - Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) - ... Seite 1
Source: wallstreet-online.de
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a...
Lishan Aklog Lucid Diagnostics Inc Pavmed Inc Prnewswire Lucid Diagnostics Inc Moldx Program Mol Noridian Healthcare Solutions
Source: prnewswire.com
PAVMED INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Item 7.01. Regulation FD Disclosure. On March 31, 2023, Lucid Diagnostics Inc. , a majority owned subsidiary of PAVmed Inc. , issued a press release announcing that, on March 30, 2023, the MolDX... | April 3, 2023
Securities Exchange Pavmed Inc Moldx Program Lucid Diagnostics Inc Lucid Diagnostics Securities Exchange Act
Source: marketscreener.com